Elicio Therapeutics, a clinical-stage biotech focused on immunotherapies for mutant KRAS-driven cancers using its proprietary Amphiphile (AMP) technology, is advancing its lead candidate ELI-002 7P in pancreatic cancer with an anticipated pivotal disease-free survival analysis in H1 2026. The company’s off-the-shelf approach targets lymph nodes to elicit robust T cell responses, potentially overcoming limitations of conventional immunotherapies. Despite promising early clinical data and a diversified preclinical pipeline targeting BRAF and TP53 mutations, ELTX faces significant operating losses and liquidity constraints. The firm relies on capital raises to sustain operations and fund clinical development. Investors should monitor upcoming trial data and financing developments as critical factors shaping ELTX’s outlook.